source
- Altimmune’s pemvidutide cuts heavy drinking days in phase 2 AUD trialAltimmune announced that its experimental dual GLP-1/glucagon receptor agonist pemvidutide reduced heavy drinking in a phase‑2 study of alcohol use disorder. In the 24‑week Reclaim trial, particip…
- Boston Scientific launches multi-year restructuring plan, foresees $500 million annual savings and job cutsBoston Scientific announced a global restructuring program that will run from this year through 2029, aiming to streamline its supply chain and reorganize functions. The plan involves moving certa…